The well-controlled MAPK/ERK cascade experiences unchecked overactivation in various cancers due to the activation of mutations in components of the MAPK cascade, which drives constitutive signaling, rendering it an always-on pathway (Table 1). This evidence concerns the gene MAPK1 and cancer.